^
Association details:
| Biomarker: | CLU-NRG1 fusion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | seribantumab (MM-121) (HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
Published date:
10/09/2020
Excerpt:
Administration of seribantumab (0.6-10 mg, BIW) to mice bearing LUAD-0061AS3 or OV-10-0050 (ovarian cancer PDX, CLU/NRG1 fusion) PDX tumors significantly reduced tumor growth, leading to approximately 60% and 100% regression in tumor size, respectively.
